DYSREGULATION OF THE AUTONOMIC NERVOUS SYSTEM IN THE MECHANISMS OF METABOLIC SYNDROME DEVELOPMENT

The concept of metabolic syndrome as a cluster of risk factors for type 2 diabetes and cardiovascular diseases has undergone a number of evolutionary transformations over the past years. Incorporation of autonomic nervous system dysfunction into the pathogenesis of metabolic syndrome opens an opportunity for inclusion of a number of clinical entities in the cluster of metabolic syndrome as they mutually affect the course and clinical manifestations of pathologies involved in metabolic syndrome. To confirm this notion, a cross-sectional transverse study of a continuous sample of 158 patients with metabolic syndrome was performed. The study showed that, in the presence of metabolic syndrome, the incidence of cardiac autonomic neuropathy reaches 37.5%. A number of features of gastroesophageal reflux disease in patients with metabolic syndrome were found in the structure of complaints where regurgitation predominated. Fibrogastroduodenoscopy demonstrated endoscopically negative form of the disease in 38%, and, according to high DeMeester index by daily pH-metry, the alkaline reflux was present in patients in lying position over 25% of time. Young men with metabolic syndrome had high incidence of prostatic enlargement (increased prostate size and volume) as well as high incidence of the IPSS questionnaire  score corresponding to the initial manifestations of prostatic hyperplasia in the presence of insulin resistance and normal androgen levels. The study showed that dysfunction of the autonomic nervous system (along with insulin resistance) was the main converging point in the development of metabolic syndrome. This suggests that cardiac autonomic neuropathy, lower urinary tract symptoms, and gastroesophageal reflux disease may be included in the metabolic syndrome cluster. 

1. Grundy S. M. Obesity, Metabolic Syndrome and Cardiovascular Disease. J. Clin. Endocrinol. Metab. 2004; 89: 2595–2600.

2. Lorenzo C., Williams K., Hunt K. J., Haffner S. M. The National Cholesterol Education Program — Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care. 2007; 30(1): 8–13.

3. Reaven G. M. The metabolic syndrome: is this diagnosis necessary? Am. J. Clin. Nutr. 2006; 6(83): 1237–1247.

4. Standi E. Aetiology and consenquences of the metabolic syndrome. Eur. Heart J. 2005; 7: 10–13.

5. Pashenceva A. V., Verbovoy A. F., Sharonova L. A. Insulin resistance in the therapeutic clinic. Ozhirenie i metabolizm. 2017; 14(2): 9–17 (In Russ).

6. McCary M. Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha1-adrenergic receptors on adypocytes. Med. Hypothes. 2004; 62(5): 830–838.

7. Di Bona G. F. Sympathetic nervous system and the kidney in hypertension. Curr. Opin. Nephrol. Hypertens. 2002; 11: 197–200.

8. Katsiki N., Georgiadou E., Hatzitolios A. I. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs. 2009; 69(11): 1417–1431.

9. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews. 2010; 11(6): 430–445.

10. Vakil N., van Zanten S., Kahrilas P., Dent J., Jones R.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am. J. Gastroenterol. 2006; 101: 1900–1920.

11. Task Force of the European Society of Cardiology and the American Society of Pacing Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996; 93: 1043–1065.

12. Kseneva S. I., Borodulina E. V., Trifonova O. Y., Udut V. V. Cardiac Autonomic Drive during Arterial Hypertension and Metabolic Disturbances. Bulletin of Experimental Biology and Medicine. 2016; 161(2): 237–240.

13. Bray G. Drag treatment of the overweight patient. World J. Gastroenterol. 2007; 132(6): 2239–2252.

14. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. Br. J. Urol. International. 2006; 97(2): 23–28.